Shared on 10 Aug 25
Fair value Increased 11%Viemed Healthcare’s consensus price target has increased to $13.00, reflecting improvements in profitability and valuation as evidenced by a higher net profit margin and a lower future P/E. What's in the News Raised 2025 net revenue guidance to $271–$277 million, up from $256–$265 million, driven by inclusion of Lehan's anticipated results.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 11%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 3.80%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget has decreased revenue growth from 13.9% to 11.9%.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 11 Mar 25
Fair value Increased 7.40%AnalystConsensusTarget has decreased future PE multiple from 25.4x to 22.8x.